BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 9, 2026
Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
Neurology/psychiatric RSS Feed RSS

Neurology/psychiatric

Norwegian University of Science and Technology divulges new CSF-1R inhibitors

May 10, 2024
Norwegian University of Science and Technology (NTNU) has synthesized macrophage colony-stimulating factor 1 receptor (CSF-1R; CD115; c-Fms) inhibitors reported to be useful for the treatment of cancer, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, macular degeneration, osteoarthritis, osteoporosis, rheumatoid arthritis and Alzheimer’s disease, among others.
Read More
Pill in immersive interface

Bio Korea 2024: AI teeters toward ‘necessity’ in new drug R&D

May 9, 2024
By Marian (YoonJee) Chu
As the average cost of new drug R&D continues to skyrocket, the perception around using artificial intelligence (AI) as a tool to boost drug discovery is changing. “Developing new AI-based drugs is a difficult task, not only for Korea but also for countries with leading AI technology,” Hyeyun Jung, principal researcher of Korea Health Industry Development Institute’s Center for Health Industry Policy, told the audience at the Bio Korea meeting on May 9. “But there is a change in perception; [namely that] applying AI to new drug development is not an option but a necessity.”
Read More
3D illustration of transparent human torso with close up of spinal cord

Red light therapy found to help regenerate spinal cord cells

May 9, 2024
By Shani Alexander
Researchers have developed a method to repair nerve connections in patients with spinal cord injuries using red and near-infrared light. The team from the University of Birmingham, U.K., are now planning to develop an implantable device to help surgeons protect and repair the spinal cord.
Read More
Cranius
Patents

Cranius reveals drug reservoir design for brain drug delivery device

May 9, 2024
By Simon Kerton
The latest patent filing from Cranius LLC describes a reservoir for its implanted drug delivery devices which is shaped and formed to empty and fill reliably without any concern for neighboring organ impingement or compression, and which can precisely control and monitor exactly just how much of a medicine is being delivered.
Read More
Microscope with beakers and flasks
Drug design, drug delivery & technologies

Avicenna extends machine learning platform to enhance medicinal chemistry

May 9, 2024
Avicenna Biosciences Inc. has introduced an extension to its machine learning (ML) technology platform to enhance medicinal chemistry and expedite clinical-stage drug discovery.
Read More
Psychedelic drug- brain illustration

EMA reconsiders psychedelics for mental health disorders

May 8, 2024
By Nuala Moran
The EMA’s chief medical officer has expressed disquiet that Europe has fallen behind in the development of psychedelic drugs as approved therapies for mental disorders, saying they should be given “a second chance.”
Read More
Neurology/psychiatric

Kissei Pharmaceutical presents new orexin OX2 receptor agonists for narcolepsy

May 8, 2024
Kissei Pharmaceutical Co. Ltd. has divulged orexin OX2 receptor agonists reported to be useful for the treatment of narcolepsy.
Read More
Neurology/psychiatric

B&A Oncomedical divulges new NKCC1 inhibitors

May 8, 2024
B&A Oncomedical SAS has synthesized solute carrier family 12 member 2 (SLC12A2; NKCC1) inhibitors reported to be useful for the treatment of cancer, schizophrenia, autistic spectrum disorders, fragile X syndrome, Rett syndrome, Down syndrome, Parkinson’s disease and temporal lobe epilepsy, among others.
Read More
Illustration showing the difference between focal and generalized seizures
Neurology/psychiatric

Saniona begins preclinical development of SAN-2355 for focal onset seizures

May 8, 2024
Saniona AB has initiated preclinical development of SAN-2355, a potential best-in-class and new-generation Kv7.2/Kv7.3 activator for the treatment of focal onset seizures.
Read More
Justin Hanka, CEO, Mindbio
Newco news

Mindbio explores psychedelic potential of LSD for depression, PMS

May 7, 2024
By Tamra Sami
The use of psychedelics is seeing impressive results in treating psychiatric disorders like treatment-resistant depression and post-traumatic stress disorder, and Mindbio Therapeutics Ltd. is expanding the field to include microdoses of lysergic acid diethylamide (LSD) to treat depression and premenstrual syndrome.
Read More
Previous 1 2 … 181 182 183 184 185 186 187 188 189 … 3016 3017 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 8, 2026.
  • Hengrui discovers new Nav1.8 blockers

    BioWorld Science
    Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
  • Cancer and blood cells

    Hematopoietic stem cell research points to leukemia’s early roots

    BioWorld Science
    Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • 3D illustration of antibodies

    Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

    BioWorld Science
    Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing